Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | CLTC | Q00610 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851692 | 0.93 | MEN1 (0.56) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL14557198 | 0.86 | MEN1 (0.49) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL3852184 | 0.86 | MEN1 (0.49) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL3852391 | 0.85 | FTO (0.53) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL3853314 | 0.84 | MEN1 (0.69) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL4143779 | 0.81 | MEN1 (0.59) | MEN1KMT2APOLBSMN1; SMN2FTO | |
| SCHEMBL5107206 | 0.81 | FTO (0.64) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL2023426 | 0.80 | FTO (0.63) | MEN1KMT2APOLBFTOPABPC1 | |
| SCHEMBL3850328 | 0.79 | MEN1 (0.76) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL3860903 | 0.77 | FTO (0.48) | MEN1KMT2APOLBCASP6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | MEN1 3865/4885KMT2A 4267/4885POLB 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.